AMGEN INC (1AMGN.MI) Fundamental Analysis & Valuation

BIT:1AMGN • US0311621009

329.15 EUR
+14.1 (+4.48%)
Last: Mar 2, 2026, 07:00 PM

This 1AMGN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall 1AMGN gets a fundamental rating of 5 out of 10. We evaluated 1AMGN against 83 industry peers in the Biotechnology industry. 1AMGN has an excellent profitability rating, but there are concerns on its financial health. 1AMGN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

8

1. 1AMGN.MI Profitability Analysis

1.1 Basic Checks

  • 1AMGN had positive earnings in the past year.
  • 1AMGN had a positive operating cash flow in the past year.
  • In the past 5 years 1AMGN has always been profitable.
  • Each year in the past 5 years 1AMGN had a positive operating cash flow.
1AMGN.MI Yearly Net Income VS EBIT VS OCF VS FCF1AMGN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

1.2 Ratios

  • 1AMGN has a Return On Assets of 8.51%. This is in the better half of the industry: 1AMGN outperforms 79.52% of its industry peers.
  • 1AMGN's Return On Equity of 89.06% is amongst the best of the industry. 1AMGN outperforms 98.80% of its industry peers.
  • 1AMGN has a Return On Invested Capital of 16.85%. This is amongst the best in the industry. 1AMGN outperforms 93.98% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1AMGN is above the industry average of 12.16%.
  • The last Return On Invested Capital (16.85%) for 1AMGN is above the 3 year average (14.35%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROIC 16.85%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
1AMGN.MI Yearly ROA, ROE, ROIC1AMGN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100 150

1.3 Margins

  • Looking at the Profit Margin, with a value of 20.98%, 1AMGN is in the better half of the industry, outperforming 79.52% of the companies in the same industry.
  • 1AMGN's Profit Margin has declined in the last couple of years.
  • 1AMGN has a Operating Margin of 34.19%. This is amongst the best in the industry. 1AMGN outperforms 85.54% of its industry peers.
  • 1AMGN's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 73.30%, 1AMGN is in the better half of the industry, outperforming 60.24% of the companies in the same industry.
  • 1AMGN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
1AMGN.MI Yearly Profit, Operating, Gross Margins1AMGN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

3

2. 1AMGN.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1AMGN is creating value.
  • 1AMGN has more shares outstanding than it did 1 year ago.
  • 1AMGN has less shares outstanding than it did 5 years ago.
  • 1AMGN has a better debt/assets ratio than last year.
1AMGN.MI Yearly Shares Outstanding1AMGN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
1AMGN.MI Yearly Total Debt VS Total Assets1AMGN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • 1AMGN has a debt to FCF ratio of 6.74. This is a slightly negative value and a sign of low solvency as 1AMGN would need 6.74 years to pay back of all of its debts.
  • The Debt to FCF ratio of 1AMGN (6.74) is better than 77.11% of its industry peers.
  • 1AMGN has a Debt/Equity ratio of 5.78. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 5.78, 1AMGN is doing worse than 68.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Altman-Z N/A
ROIC/WACC1.96
WACC8.6%
1AMGN.MI Yearly LT Debt VS Equity VS FCF1AMGN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • 1AMGN has a Current Ratio of 1.14. This is a normal value and indicates that 1AMGN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.14, 1AMGN is doing worse than 66.27% of the companies in the same industry.
  • 1AMGN has a Quick Ratio of 1.14. This is a bad value and indicates that 1AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 1AMGN has a worse Quick ratio (0.90) than 67.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.9
1AMGN.MI Yearly Current Assets VS Current Liabilites1AMGN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

4

3. 1AMGN.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 10.24% over the past year.
  • Measured over the past 5 years, 1AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.65% on average per year.
  • The Revenue has grown by 9.95% in the past year. This is quite good.
  • Measured over the past years, 1AMGN shows a small growth in Revenue. The Revenue has been growing by 7.65% on average per year.
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.03% on average over the next years.
  • The Revenue is expected to grow by 2.56% on average over the next years.
EPS Next Y3.12%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
EPS Next 5Y4.03%
Revenue Next Year2.04%
Revenue Next 2Y2.46%
Revenue Next 3Y1.68%
Revenue Next 5Y2.56%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1AMGN.MI Yearly Revenue VS Estimates1AMGN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
1AMGN.MI Yearly EPS VS Estimates1AMGN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

5

4. 1AMGN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.42, 1AMGN is valued on the expensive side.
  • Based on the Price/Earnings ratio, 1AMGN is valued cheaply inside the industry as 85.54% of the companies are valued more expensively.
  • 1AMGN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 16.89, which indicates a correct valuation of 1AMGN.
  • Based on the Price/Forward Earnings ratio, 1AMGN is valued cheaply inside the industry as 89.16% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, 1AMGN is valued a bit cheaper.
Industry RankSector Rank
PE 17.42
Fwd PE 16.89
1AMGN.MI Price Earnings VS Forward Price Earnings1AMGN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, 1AMGN is valued cheaply inside the industry as 81.93% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 25.3
EV/EBITDA N/A
1AMGN.MI Per share data1AMGN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1AMGN does not grow enough to justify the current Price/Earnings ratio.
  • 1AMGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.58
PEG (5Y)3.08
EPS Next 2Y3.35%
EPS Next 3Y2.5%

6

5. 1AMGN.MI Dividend Analysis

5.1 Amount

  • 1AMGN has a Yearly Dividend Yield of 2.74%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.66, 1AMGN pays a better dividend. On top of this 1AMGN pays more dividend than 93.98% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, 1AMGN pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.74%

5.2 History

  • The dividend of 1AMGN is nicely growing with an annual growth rate of 9.41%!
Dividend Growth(5Y)9.41%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
1AMGN.MI Yearly Income VS Free CF VS Dividend1AMGN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1AMGN.MI Fundamentals: All Metrics, Ratios and Statistics

AMGEN INC

BIT:1AMGN (3/2/2026, 7:00:00 PM)

329.15

+14.1 (+4.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03
Earnings (Next)04-29
Inst Owners83.87%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap177.24B
Revenue(TTM)36.75B
Net Income(TTM)7.71B
Analysts72.2
Price Target286.55 (-12.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.74%
Yearly Dividend7.64
Dividend Growth(5Y)9.41%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.92%
Min EPS beat(2)9.56%
Max EPS beat(2)10.28%
EPS beat(4)4
Avg EPS beat(4)10.8%
Min EPS beat(4)9.56%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)6.29%
EPS beat(12)11
Avg EPS beat(12)5.41%
EPS beat(16)14
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)3.3%
Min Revenue beat(2)2.11%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.22%
Revenue beat(16)6
Avg Revenue beat(16)-0.27%
PT rev (1m)0%
PT rev (3m)1.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)2.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.09%
Valuation
Industry RankSector Rank
PE 17.42
Fwd PE 16.89
P/S 5.58
P/FCF 25.3
P/OCF 20.58
P/B 23.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)18.9
EY5.74%
EPS(NY)19.49
Fwd EY5.92%
FCF(TTM)13.01
FCFY3.95%
OCF(TTM)16
OCFY4.86%
SpS59.03
BVpS13.91
TBVpS-51.88
PEG (NY)5.58
PEG (5Y)3.08
Graham Number76.9
Profitability
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROCE 19.3%
ROIC 16.85%
ROICexc 19.6%
ROICexgc 73.08%
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
FCFM 22.04%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
ROICexc(3y)16.88%
ROICexc(5y)18.44%
ROICexgc(3y)72.7%
ROICexgc(5y)79.08%
ROCE(3y)16.43%
ROCE(5y)17.69%
ROICexgc growth 3Y-3.21%
ROICexgc growth 5Y2.03%
ROICexc growth 3Y4.63%
ROICexc growth 5Y5.17%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
F-Score7
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.06%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 105.05%
Current Ratio 1.14
Quick Ratio 0.9
Altman-Z N/A
F-Score7
WACC8.6%
ROIC/WACC1.96
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.09%
Cap/Sales(5y)3.84%
Profit Quality(3y)156.25%
Profit Quality(5y)149.01%
High Growth Momentum
Growth
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
EPS Next Y3.12%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
EPS Next 5Y4.03%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%
Revenue Next Year2.04%
Revenue Next 2Y2.46%
Revenue Next 3Y1.68%
Revenue Next 5Y2.56%
EBIT growth 1Y73.11%
EBIT growth 3Y16.9%
EBIT growth 5Y12.12%
EBIT Next Year31.54%
EBIT Next 3Y9.81%
EBIT Next 5Y8.24%
FCF growth 1Y-22.07%
FCF growth 3Y-2.67%
FCF growth 5Y-3.91%
OCF growth 1Y-13.33%
OCF growth 3Y0.81%
OCF growth 5Y-1.05%

AMGEN INC / 1AMGN.MI FAQ

What is the ChartMill fundamental rating of AMGEN INC (1AMGN.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1AMGN.MI.


What is the valuation status of AMGEN INC (1AMGN.MI) stock?

ChartMill assigns a valuation rating of 5 / 10 to AMGEN INC (1AMGN.MI). This can be considered as Fairly Valued.


How profitable is AMGEN INC (1AMGN.MI) stock?

AMGEN INC (1AMGN.MI) has a profitability rating of 8 / 10.


What is the valuation of AMGEN INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AMGEN INC (1AMGN.MI) is 17.42 and the Price/Book (PB) ratio is 23.67.


Is the dividend of AMGEN INC sustainable?

The dividend rating of AMGEN INC (1AMGN.MI) is 6 / 10 and the dividend payout ratio is 0%.